148 related articles for article (PubMed ID: 38310190)
1. Combined effects of naringin and doxorubicin on the JAK/STAT signaling pathway reduce the development and spread of breast cancer cells.
Effat H; Abosharaf HA; Radwan AM
Sci Rep; 2024 Feb; 14(1):2824. PubMed ID: 38310190
[TBL] [Abstract][Full Text] [Related]
2. Naringin treatment improves functional recovery by increasing BDNF and VEGF expression, inhibiting neuronal apoptosis after spinal cord injury.
Rong W; Wang J; Liu X; Jiang L; Wei F; Hu X; Han X; Liu Z
Neurochem Res; 2012 Aug; 37(8):1615-23. PubMed ID: 22453521
[TBL] [Abstract][Full Text] [Related]
3. Naringin inhibits thyroid cancer cell proliferation and induces cell apoptosis through repressing PI3K/AKT pathway.
Zhou J; Xia L; Zhang Y
Pathol Res Pract; 2019 Dec; 215(12):152707. PubMed ID: 31727500
[TBL] [Abstract][Full Text] [Related]
4. NFκBP65 transcription factor modulates resistance to doxorubicin through ABC transporters in breast cancer.
Velaei K; Samadi N; Soltani S; Barazvan B; Soleimani Rad J
Breast Cancer; 2017 Jul; 24(4):552-561. PubMed ID: 27878697
[TBL] [Abstract][Full Text] [Related]
5. [Norcantharidin potentialize the chemosensitivity of adriamycin through the NF-κB/IκBα signaling pathway].
Song XN; Du HF; Yu LJ; Meng YF; Lü HY; Sun LX; Meng JB; Zhang JQ
Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):809-13. PubMed ID: 22339951
[TBL] [Abstract][Full Text] [Related]
6. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy with stattic enriches the anti-proliferative effect of doxorubicin in human ZR-75-1 breast cancer cells via arresting cell cycle and inducing apoptosis.
Khaki-Khatibi F; Ghorbani M; Sabzichi M; Ramezani F; Mohammadian J
Biomed Pharmacother; 2019 Jan; 109():1240-1248. PubMed ID: 30551374
[TBL] [Abstract][Full Text] [Related]
8. Wogonin induces apoptosis and down-regulates survivin in human breast cancer MCF-7 cells by modulating PI3K-AKT pathway.
Huang KF; Zhang GD; Huang YQ; Diao Y
Int Immunopharmacol; 2012 Feb; 12(2):334-41. PubMed ID: 22182776
[TBL] [Abstract][Full Text] [Related]
9. Combination of mitochondria targeting doxorubicin with Bcl-2 function-converting peptide NuBCP-9 for synergistic breast cancer metastasis inhibition.
Yang J; Li Q; Zhou R; Zhou M; Lin X; Xiang Y; Xie D; Huang Y; Zhou Z
J Mater Chem B; 2021 Feb; 9(5):1336-1350. PubMed ID: 33443508
[TBL] [Abstract][Full Text] [Related]
10. Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway.
Ryu K; Susa M; Choy E; Yang C; Hornicek FJ; Mankin HJ; Duan Z
BMC Cancer; 2010 May; 10():187. PubMed ID: 20459702
[TBL] [Abstract][Full Text] [Related]
11. Naringin Targets NFKB1 to Alleviate Oxygen-Glucose Deprivation/Reoxygenation-Induced Injury in PC12 Cells Via Modulating HIF-1α/AKT/mTOR-Signaling Pathway.
Cao W; Feng SJ; Kan MC
J Mol Neurosci; 2021 Jan; 71(1):101-111. PubMed ID: 32557145
[TBL] [Abstract][Full Text] [Related]
12. The synergistic effect between vanillin and doxorubicin in ehrlich ascites carcinoma solid tumor and MCF-7 human breast cancer cell line.
Elsherbiny NM; Younis NN; Shaheen MA; Elseweidy MM
Pathol Res Pract; 2016 Sep; 212(9):767-77. PubMed ID: 27493101
[TBL] [Abstract][Full Text] [Related]
13. Naringin inhibits growth potential of human triple-negative breast cancer cells by targeting β-catenin signaling pathway.
Li H; Yang B; Huang J; Xiang T; Yin X; Wan J; Luo F; Zhang L; Li H; Ren G
Toxicol Lett; 2013 Jul; 220(3):219-28. PubMed ID: 23694763
[TBL] [Abstract][Full Text] [Related]
14. Aqua-(2-formylbenzoato)triphenyltin(IV) induces cell cycle arrest and apoptosis in hypoxic triple negative breast cancer cells.
Singh V; Rana NK; Kashif M; Manna PP; Basu Baul TS; Koch B
Toxicol In Vitro; 2023 Feb; 86():105484. PubMed ID: 36252919
[TBL] [Abstract][Full Text] [Related]
15. USP37 downregulation elevates the Chemical Sensitivity of Human Breast Cancer Cells to Adriamycin.
Qin T; Cui XY; Xiu H; Huang C; Sun ZN; Xu XM; Li LH; Yue L
Int J Med Sci; 2021; 18(2):325-334. PubMed ID: 33390801
[No Abstract] [Full Text] [Related]
16. The synergistic effect of 2,3,5,4'-Tetrahydroxystilbene-2-O-β-d-glucoside combined with Adriamycin on MCF-7 breast cancer cells.
Shen J; Zhang Y; Shen H; Pan H; Xu L; Yuan L; Ding Z
Drug Des Devel Ther; 2018; 12():4083-4094. PubMed ID: 30555223
[TBL] [Abstract][Full Text] [Related]
17. Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells.
Chewchuk S; Guo B; Parissenti AM
PLoS One; 2017; 12(2):e0172244. PubMed ID: 28196134
[TBL] [Abstract][Full Text] [Related]
18. Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways.
Siddiqa A; Long LM; Li L; Marciniak RA; Kazhdan I
BMC Cancer; 2008 May; 8():129. PubMed ID: 18454859
[TBL] [Abstract][Full Text] [Related]
19. CDK4 inhibition and doxorubicin mediate breast cancer cell apoptosis through Smad3 and survivin.
Tarasewicz E; Hamdan R; Straehla J; Hardy A; Nunez O; Zelivianski S; Dokic D; Jeruss JS
Cancer Biol Ther; 2014 Oct; 15(10):1301-11. PubMed ID: 25006666
[TBL] [Abstract][Full Text] [Related]
20. Enhanced therapeutic efficacy of doxorubicin/cyclophosphamide in combination with pitavastatin or simvastatin against breast cancer cells.
Dewidar SA; Hamdy O; Soliman MM; El Gayar AM; El-Mesery M
Med Oncol; 2023 Dec; 41(1):7. PubMed ID: 38051378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
